{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red14\green86\blue140;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red107\green107\blue106;
\red255\green255\blue102;
\red190\green190\blue252;
\red80\green80\blue80;
\red51\green51\blue51;
\red254\green254\blue0;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red246\green246\blue246;
\red21\green137\blue21;
\red247\green247\blue247;
\red238\green238\blue238;
\red20\green93\blue164;
\red181\green79\blue104;
\red233\green233\blue233;
\red112\green112\blue112;
\red0\green114\blue54;
\red240\green240\blue240;
\red105\green105\blue105;
\red106\green144\blue39;
\red187\green187\blue187;
\red255\green255\blue174;
\red255\green248\blue96;
\red232\green233\blue232;
\red249\green249\blue249;
\red118\green118\blue118;
\red239\green122\blue2;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red204\green255\blue255;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red236\green236\blue236;
\red127\green127\blue127;
\red149\green246\blue220;
\red227\green227\blue227;
\red71\green120\blue194;
\red102\green0\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Ni-Q, LLC v. Prolacta Bioscience, Inc., 367 F.Supp.3d 1221 (2019)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_97}{\*\bkmkend co_document_97}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I684ad680307611e987fd8441446aa305_Target}{\*\bkmkend I684ad680307611e987fd8441446aa305_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
367 F.Supp.3d 1221
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Oregon.
\par 
}
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5056729449)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
NI-Q, LLC
}}}
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
, Plaintiff,
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
PROLACTA BIOSCIENCE, INC., Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Case No. 3:17-cv-934-SI
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed February 13, 2019
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_97}{\*\bkmkend co_synopsis_97}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Competitor brought action seeking declaration that it did not infringe patent related to methods for testing milk from human donors and that patent was invalid. Assignee of patent counterclaimed for infringement. Competitor moved for partial summary judgment.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The District Court, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0108867101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael H. Simon
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, J., held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claim was directed to patent-ineligible subject matter;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claim did not contain inventive concept sufficient to render claim directed to law of nature patent eligible; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
accused testing product did not infringe patent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Motion granted.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_97}{\*\bkmkend co_attorneysAndLawFirms_97}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1223_97}{\*\bkmkend co_pp_sp_7903_1223_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1223
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0338622301&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Brenna K. Legaard
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0501768899&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Angela E. Addae
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Schwabe, Williamson & Wyatt pc, 1211 SW Fifth Avenue, Suite 1900, Portland, OR 97204. Of Attorneys for Plaintiff.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337381301&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kristin L. Cleveland
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Klarkquist Sparkman LLP, 121 SW Salmon Street, Suite 1600, Portland, OR 97204; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0335464801&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Orion Armon
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Cooley LLP, 380 Interlocken Crescent, Suite 900, Broomfield, CO 80021; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0501398399&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alexandra Mayhugh
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Cooley LLP, 1333 2nd Street, Suite 400, Santa Monica, CA 90401; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0488257801&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nicholas G. Lockhart
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC 20004. Of Attorneys for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_97}{\*\bkmkend co_opinion_97}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I439f0352f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I439f0352f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43af5701f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43af5701f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43af5701f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43af5701f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb800 
OPINION AND ORDER
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0108867101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael H. Simon
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, District Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In this patent action, Plaintiff Ni-Q, LLC (\u8220\'3fNi-Q\u8221\'3f) seeks a declaration that it has not infringed 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,628,921 (\u8220\'3fthe \lquote 921 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (relating to methods for testing milk from human donors). Ni-Q also seeks a declaration that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid. Ni-Q further seeks money damages and injunctive relief under Oregon\rquote s Unlawful Trade Practices Act. By counterclaim, Defendant Prolacta Bioscience, Inc. (\u8220\'3fProlacta\u8221\'3f) seeks money damages and injunctive relief against Ni-Q. Prolacta alleges that the inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have assigned their rights in that patent to Prolacta and that Ni-Q has infringed at least Claims 1, 2, and 9 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On June 12, 2018, the Court issued its Opinion and Order on Claim Construction. The Court adopted the parties\rquote  stipulated construction of the term \u8220\'3fwherein a match.\u8221\'3f The Court also construed the disputed term \u8220\'3fprocessing\u8221\'3f in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before the Court is Ni-Q\rquote s motion for partial summary judgment on two alternative grounds. First, Ni-Q argues that, based on the Court\rquote s construction of the term \u8220\'3fprocessing,\u8221\'3f Claims 1, 2, 4, 6, 7, 8, 9, and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for failing to claim patentable subject matter. Second, Ni-Q argues that it has not infringed any claim of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1224_97}{\*\bkmkend co_pp_sp_7903_1224_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1224
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because Ni-Q does not perform all of the steps required under the patent, as construed by the Court. For the reasons discussed below, Ni-Q\rquote s motion is granted on both grounds.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b08f81f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b08f81f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
STANDARDS
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b08f81f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b08f81f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Summary Judgment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12047531000_97}{\*\bkmkend co_anchor_B12047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A party is entitled to summary judgment if the \u8220\'3fmovant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 56(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The moving party has the burden of establishing the absence of a genuine dispute of material fact. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132677&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_323" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Celotex Corp. v. Catrett
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 477 U.S. 317, 323, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court must view the evidence in the light most favorable to the non-movant and draw all reasonable inferences in the non-movant\rquote s favor. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001456078&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1257" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Clicks Billiards Inc. v. Sixshooters Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 251 F.3d 1252, 1257 (9th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although \u8220\'3f[c]redibility determinations, the weighing of the evidence, and the drawing of legitimate inferences from the facts are jury functions, not those of a judge 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
... ruling on a motion for summary judgment,\u8221\'3f the \u8220\'3fmere existence of a scintilla of evidence in support of the plaintiff\rquote s position [is] insufficient ....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132674&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_252&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_252" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. Liberty Lobby, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 477 U.S. 242, 252, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fWhere the record taken as a whole could not lead a rational trier of fact to find for the non-moving party, there is no genuine issue for trial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986115992&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_587&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_587" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Matsushita Elec. Indus. Co. v. Zenith Radio Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 475 U.S. 574, 587, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation and quotation marks omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b1c801f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b1c801f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b1c801f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b1c801f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22047531000_97}{\*\bkmkend co_anchor_B22047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fWhether a claim is drawn to patent-eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a threshold inquiry\u8221\'3f and \u8220\'3fan issue of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017388082&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_950&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_950" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Bilski
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 545 F.3d 943, 950-51 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides: \u8220\'3fWhoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f \u8220\'3fThe [Supreme] Court has long held that this provision contains an important implicit exception. \u8216\'3f[L]aws of nature, natural phenomena, and abstract ideas\u8217\'3f are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_70&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_70" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 70, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (first alteration added, second alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32047531000_97}{\*\bkmkend co_anchor_B32047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42047531000_97}{\*\bkmkend co_anchor_B42047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
There is two-step test to determine patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The first step is to determine whether the claims are directed to a patent-ineligible subject matter, such as a naturally occurring phenomenon. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\rquote l
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. 208, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The second step is to \u8220\'3fconsider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 78, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). An \u8220\'3finventive concept\u8221\'3f is \u8220\'3fan element or combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72-73, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b375b1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b375b1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b375b1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b375b1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
C. Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52047531000_97}{\*\bkmkend co_anchor_B52047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62047531000_97}{\*\bkmkend co_anchor_B62047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
An infringement analysis also involves a two-step process. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041455684&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1358&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1358" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phil-Insul Corp. v. Airlite Plastics Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 854 F.3d 1344, 1358 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fThe court must: (1) determine the scope and meaning of the patent claims asserted; and (2) compare the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1225_97}{\*\bkmkend co_pp_sp_7903_1225_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1225
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 properly construed claims to the allegedly infringing device.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041455684&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fWith regard to the second step of the infringement analysis, the patentee must prove that the accused device embodies every limitation in the claim, either literally or by a substantial equivalent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1994020320&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1573&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1573" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Conroy v. Reebok Int\rquote l, Ltd.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 14 F.3d 1570, 1573 (Fed. Cir. 1994)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72047531000_97}{\*\bkmkend co_anchor_B72047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82047531000_97}{\*\bkmkend co_anchor_B82047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fLiteral infringement exists when every limitation recited in the claim is found in the accused device.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038192322&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1341&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1341" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Akzo Nobel Coatings, Inc. v. Dow Chem. Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 811 F.3d 1334, 1341 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In considering literal infringement at summary judgment, a court must resolve all inferences in favor of the patentee and may grant summary judgment against the patentee only if the court determines that no reasonable jury could find infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038192322&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92047531000_97}{\*\bkmkend co_anchor_B92047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102047531000_97}{\*\bkmkend co_anchor_B102047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fWhile infringement under the doctrine of equivalents is a question of fact, \u8216\'3f[w]here the evidence is such that no reasonable jury could determine two elements to be equivalent, district courts are obliged to grant partial or complete summary judgment.\u8217\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037579539&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1319&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1319" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Advanced Steel Recovery, LLC v. X-Body Equip., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 808 F.3d 1313, 1319 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997060689&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_39&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_39" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Jenkinson Co. v. Hilton Davis Chem. Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 520 U.S. 17, 39 n.8, 117 S.Ct. 1040, 137 L.Ed.2d 146 (1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In making this determination, \u8220\'3fthe range of equivalents cannot be divorced from the scope of the claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000358931&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1382&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1382" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vehicular Techs. Corp. v. Titan Wheel Int\rquote l, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 212 F.3d 1377, 1382 (Fed. Cir. 2000)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (per curiam). Indeed, \u8220\'3fby defining the claim in a way that clearly exclude[s] certain subject matter,\u8221\'3f a patent may \u8220\'3fimplicitly disclaim[ ] the subject matter that was excluded and thereby bar[ ] the patentee from asserting infringement under the doctrine of equivalents.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001211983&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1346&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1346" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 242 F.3d 1337, 1346 (Fed. Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alterations added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b57181f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b57181f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
BACKGROUND
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states as follows, with the terms construed by the Court in bold:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
A method for determining whether a donated [human] mammary fluid was obtained from a specific subject, the method comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(a) testing a donated biological sample from the specific subject to obtain at least one reference identity marker profile for at least one marker;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) testing a sample of the donated mammary fluid to obtain at least one identity marker profile for the at least one marker in step (a);
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c) comparing the identity marker profiles, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein a match
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 between the identity marker profiles indicates that the mammary fluid was obtained from the specific subject; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(d) 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
processing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the donated mammary fluid whose identity marker has been matched with a reference identity marker profile, wherein the processed donated mammary fluid comprises a human protein constituent of 11-20 mg/mL; a human fat constituent of 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
-55 mg/mL; and a human carbohydrate constituent of 70-120 mg/mL.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ECF 25-1 (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patent).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties stipulated, and the Court adopted, that the term \u8220\'3fwherein a match\u8221\'3f means \u8220\'3fa determination that the marker(s) in the biological sample and donated fluid or milk are the same and that there are no additional unmatched marker(s).\u8221\'3f ECF 86 at 7-8. The Court construed the term \u8220\'3fprocessing\u8221\'3f to mean: \u8220\'3fOne or more of the following: filtering, heat-treating, separating into cream and skim, adding cream to the skim, or pasteurizing.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 16. Claim 1 is representative, and the other asserted 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1226_97}{\*\bkmkend co_pp_sp_7903_1226_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1226
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims do not add anything substantive for purposes of the pending motion.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012047531000_ID0EKQBG_97}{\*\bkmkend co_fnRef_B00012047531000_ID0EKQBG_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012047531000_97" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims testing and processing methods intended to standardize nutritional content in donated human mammary fluid and to ensure that the donor of a given sample is a match to a previously-identified donor. The inventors saw this as a solution to two different problems\u8212\'3fhuman replacement milk that is nutritionally standardized (particularly important for preterm babies), and milk that is certifiably from a particular donor.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Regarding nutrition, the inventors established in the patent claims an acceptable range of protein, fat, and carbohydrates that the inventors believed was optimal for infants. Some naturally-occurring breast milk falls within these nutritional parameters. For milk that does not, the patent claims various processing steps, including filtering and adding cream, to alter the nutritional content to reach the standardized nutritional content. Regarding donor identification, the inventors established in the patent claims that a donor would provide a biological sample to obtain at least one reference identity marker. As described in the patent specification, this reference sample would come from methods known in the art, 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fsuch as, but not limited to, a cheek swab sample of cells, or a drawn blood sample, milk, saliva, hair roots, or other convenient tissue.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at 9:25-28. The reference identity marker nucleic acids would be isolated from \u8220\'3fmilk, saliva, buccal cells, hair roots, blood, and any other suitable cell or tissue\u8221\'3f using methods known in the art such as \u8220\'3fSTR analysis of STR loci, HLA analysis of HLA loci or multiple gene analysis of individual genes/alleles.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 9:28-43. When mammary fluid is then donated and sent for processing, that mammary fluid would be tested against the reference identity marker to ensure a match, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that the same woman donated both the original reference marker and the mammary fluid.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b857b1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b857b1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
DISCUSSION
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b857b1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b857b1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Invalidity
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q argues that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Claims 1, 2, 4, 6, 7, 8, 9, and 11) are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the claims patent ineligible natural law with no inventive concept to transform the natural law into patent-eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b8cce1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b8cce1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43b8cce1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43b8cce1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
1. Step One Analysis
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112047531000_97}{\*\bkmkend co_anchor_B112047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The first step under the Supreme Court\rquote s framework in considering 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invalidity is to determine whether the asserted claims are directed to patent-ineligible subject matter, such as laws of nature, natural phenomena, and abstract ideas. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_70&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_70" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 70, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1133&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1133" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharms., Inc. v. West-Ward Pharms. Int\rquote l Ltd.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1117, 1133-34 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Because \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 71, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fit is not enough to merely identify a patent-ineligible concept underlying the claim; [the court] must determine whether that patent-ineligible concept is what the claim is \u8216\'3fdirected to.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1050 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122047531000_97}{\*\bkmkend co_anchor_B122047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q argues that the presence of identity markers such as DNA and proteins in a woman\rquote s tissue or milk is natural, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1227_97}{\*\bkmkend co_pp_sp_7903_1227_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1227
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the nutritional levels required by the patent occur naturally, as alleged by Prolacta in its Answer and as found by the Court in its Opinion and Order on Claim Construction. In its briefing on the motion, Prolacta responds that the claims are directed to producing safer milk that is standardized with optimal nutritional values. Prolacta argues that the limitations in Claim 1(a) through 1(d) are directed to a novel method for selecting for processing safe milk from health-screened donors and Claim 1(d) is directed to manufacturing a nutrient-enhanced human milk product.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court agrees that the asserted claims are directed to the laws of nature. The presence of identity markers such as DNA in a woman\rquote s mammary fluid and other biological tissue is natural. Although the patent describes the human action of testing the original reference sample and the mammary fluid sample and comparing them, that does not convert the claim to patent-eligible subject matter. The relationship of the markers in the samples exists naturally. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhile it takes a human action (the administration of a thiopurine drug) to trigger a manifestation of this relation in a particular person, the relation itself exists in principle apart from any human action. The relation is a consequence of the ways in which thiopurine compounds are metabolized by the body\u8212\'3fentirely natural processes. And so a patent that simply describes that relation sets forth a natural law.\u8221\'3f). Claim 1 merely describes the natural law that two different biological samples from the same individual contain the same identity markers and thus can be tested and compared. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics, LLC
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d 1352, 1361 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fBecause the testing patents are based on the relationship between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and heightened MPO levels that exists in principle apart from human action, they are directed to a patent-ineligible law of nature.\u8221\'3f (citation and alterations omitted) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta\rquote s argument to the contrary is unpersuasive. The limitations of Claim 1(a) through 1(d) require no step, method, or process relating to safety or the health screening of donors. The limitations of the claim merely require testing a reference sample of a donor, testing a sample of the donated mammary fluid, comparing the two test results, and processing only the mammary fluid when the two tests match. Claim 1 thus ensures that mammary fluid is processed only when it is the same donor who gave both the reference sample and the mammary fluid. There is nothing in Claim 1, however, that requires testing the donor for disease or drug use or anything else relating to health or safety. Indeed, the claim itself states that it is a \u8220\'3fmethod for determining whether a donated mammary fluid was obtained from a specific subject.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at 21:46-47. The claim is about identification\u8212\'3fit does not suggest that its goal or purpose relates to safety or health concerns.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta mainly relies on text from the specification to support its theory that Claim 1 is directed to safety and health screening. First, the Court notes that the primary focus in a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis is the text of the claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 77-78, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (looking only to the text of the claims in invalidating the patent); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (focusing on the text of the claims at issue and how they differed from the claims at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and considering the specification only for how it explained the significance of the limitation set out in the claims). It is the claims that must confine the reach of the patent, not the specification. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting, in invalidating claims, that \u8220\'3fthe patent claims do not confine their reach to particular applications of those [natural] laws\u8221\'3f); 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1228_97}{\*\bkmkend co_pp_sp_7903_1228_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1228
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1374&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1374" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial, L.L.D.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1374-75 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (invalidating claim because it essentially covered all applications, even though the specification provided examples of applications to specific diseases).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Second, although the Court considers the claims in light of the specification, that only gets Prolacta so far. For example, if Claim 1 had stated a goal or purpose of safety or confirming health-screened donors, the Court could look to the specification for the means for achieving that goal in considering Ni-Q\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040226409&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1295" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Amdocs (Israel) Ltd. v. Openet Telecom, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 841 F.3d 1288, 1295 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Claim 1, however, does not include such a goal or purpose. The specification can also explain in more detail a limitation set forth in a claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The limitation of processing milk only by health-screened donors, argued by Prolacta, also is not contained within Claim 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, the specification is not specific enough to convert Claim 1 to a method for selecting safe milk from health-screened donors, even if the specification could limit the claim. The specification broadly states: \u8220\'3fTesting donors to confirm their identity improves safety of donated milk.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at 9:1-2. It provides no further detail, other than the testing 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fensures the provenance of the donated milk.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 9:3. But that merely confirms the identity of the donor, not the health of the donor or safety of the milk. Later, in Example 1, the patent provides that a woman and her biological tissues and milk \u8220\'3fwill\u8221\'3f undergo various steps, but that she \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
can
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 also be screened (using the reference sample or another sample) for, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, drug use, viruses, bacteria, parasites, and fungi 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
etc.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, to determine her health.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21:6-9 (emphasis added). Thus, the safety and health screening emphasized by Prolacta is optional even in the specification. It is, therefore, not a reasonable interpretation of Claim 1 that it is directed to a method for selecting safe milk from health-screened donors.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta\rquote s argument that Claim 1 covers a novel method of standardizing optimal nutrient level also is unavailing. As conceded by Prolacta, the nutrient levels set out in Claim 1(d) occur naturally in breast milk. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ECF 57 at 15 (Prolacta\rquote s First Am. Answer and Counterclaims at \u182\'3f\u182\'3f 22-24) (stating that it is \u8220\'3fcommon for standard, unfortified human breast milk\u8221\'3f to have the claimed nutrient ranges); ECF 25-4 at 2 (Declaration of Prolacta\rquote s Chief Executive Officer Scott A. Elster, \u182\'3f 6) (same). In those circumstances, no nutrient enhancement is required. As the Court stated in its claim construction, when the donated mammary fluid naturally falls within the claimed nutrient ranges, the only processing that is required under Claim 1 is pasteurization. When the nutrient levels do not meet the claim\rquote s limitations, other processing steps may be required, such as filtering or adding cream to skim. Claim 1, however, does not require those processing steps.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022047531000_ID0EJGAI_97}{\*\bkmkend co_fnRef_B00022047531000_ID0EJGAI_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022047531000_97" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1229_97}{\*\bkmkend co_pp_sp_7903_1229_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1229
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claim 1(d) does not require that nutrient levels of donated mammary fluid be altered. Nor does the text of the claim include anything about optimal nutrient levels. It merely requires that after processing is complete, the mammary fluid consist of wide-ranging levels of nutrients that, as conceded by Prolacta, are naturally found in human breast milk.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court provided the parties with a tentative Opinion and Order and gave them the opportunity to respond. In response, Prolacta shifted its argument at step one and now asserts that Claim 1 is directed to patent-eligible subject matter because it applies a natural phenomenon to select what milk to process. Prolacta argues that Claim 1 \u8220\'3fproduces a safer human milk product by excluding contaminated milk from processing regardless of whether known donors are health screened.\u8221\'3f Prolacta focuses on how excluding contamination from unscreened nonmatching donors creates a safer milk product. Prolacta\rquote s new argument is not persuasive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As discussed above, Claim 1 merely ensures the provenance, or origin, of the donor. If the donor is not health screened, selecting to process mammary fluid from that donor (and excluding fluid from other donors) cannot produce a safer human milk product. If that donor has an infectious disease, repeatedly processing her milk because it matches her identity profile creates a less safe milk product. Moreover, excluding milk from others, which may come from someone who does not have an infectious disease, merely because it did not come from the original, unscreened donor, does not automatically make a safer milk product. The safety of the milk product is tied to health screening of the donor, which is not required by the patent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 is a broad claim that is not limited to a particular application of natural law. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
It is not limited to commercial human breast milk production, to certain processing that alter the makeup of the breast milk, or to testing breast milk donors for viruses, bacteria, drugs, or other health issues and then ensuring that later-donated milk matches the originally-screened donor. Indeed, it purports to cover any use where: (1) a donor has donated a reference sample and mammary fluid that are tested for a match; (2) if there is a match, the donated mammary fluid is processed using any of the five types of processing; and (3) after processing, the mammary fluid contains the identified nutrient ranges. Because these nutrient ranges are found naturally in breast milk, the claim\rquote s covered use could include, for example, researchers who are testing the efficacy of DNA comparisons between breast milk and other biological samples and in so doing heat-treat or pasteurize the milk.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1, therefore, is impermissibly directed to a patent-ineligible subject. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_751&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_751" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d 743, 751\u8211\'3f52 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding claims failed at step one, even though they involved an \u8220\'3finnovative laboratory technique\u8221\'3f and \u8220\'3fconcrete steps,\u8221\'3f because they \u8220\'3frecite a natural law and conventional means for detecting it\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1361
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (invaliding claims that contained no treatment limitations and instead broadly covered \u8220\'3f \u8216\'3fseeing\u8217\'3f MPO already present in 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1230_97}{\*\bkmkend co_pp_sp_7903_1230_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1230
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a bodily sample and correlating that to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1374&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1374" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d at 1374-75
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that claims were directed to a natural phenomenon because \u8220\'3fClaim 1 covers any comparison, for any purpose, of any non-coding region sequence known to be linked with a coding region allele at a multi-allelic locus.... [A]lthough the specification does provide some examples of linked alleles known to be diagnostic of inherited diseases such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd2209475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cystic fibrosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic9d50f64475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
muscular dystrophy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[,] Claim 1 broadly covers essentially all applications, via standard experimental techniques, of the law of linkage disequilibrium to the problem of detecting coding sequences of DNA\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371, 1376 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (invalidating a patent claiming a method for detecting paternal DNA that naturally occurs in maternal serum because \u8220\'3fthe claimed method begins and ends with a naturally occurring phenomenon\u8221\'3f). The other asserted claims challenged by Ni-Q do not add anything new or substantive that alter the Court\rquote s analysis. They are also directed to a patent-ineligible subject.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43c1f4a1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43c1f4a1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43c1f4a1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43c1f4a1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
2. Step Two Analysis
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132047531000_97}{\*\bkmkend co_anchor_B132047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142047531000_97}{\*\bkmkend co_anchor_B142047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The second step of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework is to determine whether the claims contain an inventive concept sufficient to transform the claimed naturally-occurring phenomenon into a patent-eligible subject. The inventive concept must be \u8220\'3fnew and useful.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fSimply appending conventional steps, specified at a high level of generality, to laws of nature, natural phenomena, and abstract ideas cannot make those laws, phenomena, and ideas patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_82&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_82" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 82, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fTo save a patent at step two, an inventive concept must be evident in the claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1362
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation omitted); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043776259&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Berkheimer v. HP, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 881 F.3d 1360, 1369 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that \u8220\'3fimprovements in the specification\u8221\'3f must be \u8220\'3fcaptured in the claims\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152047531000_97}{\*\bkmkend co_anchor_B152047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q argues that Claim 1 contains no inventive concept sufficient to meet the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two requirements. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q asserts that Prolacta\rquote s comparison of DNA to match the reference sample to the donated mammary fluid was not new or inventive, and that this fact is admitted in the patent. Ni-Q also asserts that because processing can include mere pasteurization, that is not a new or innovative step. Ni-Q adds that none of the remaining asserted claims add anything new or inventive that render them patentable under step two.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta responds that three aspects of the claims are new or inventive: (1) applying DNA analysis to mammary fluid; (2) selecting mammary fluid for processing based on a matching processing that ensured the donated fluid was from a specific subject, thereby eliminating the risk of communicable diseases in donated milk; and (3) requiring the recited nutrient ranges. Prolacta asserts that these steps were not known in the prior art and they were not well understood, routine, or conventional. The latter two arguments by Prolacta are the same arguments Prolacta previously asserted in arguing Claim 1\rquote s validity at step one. They are rejected because, as discussed above, the elimination of health concerns and communicable diseases in processed milk is not contained in any of the asserted claims (and therefore cannot provide an inventive concept) and the required nutrient ranges may not require any processing other than pasteurization of donated milk, which is not new or inventive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta\rquote s first argument, however, that applying DNA testing to mammary fluid was an inventive concept, is a new argument. Prolacta submits the declaration of Randolph Nagy, former Vice President of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1231_97}{\*\bkmkend co_pp_sp_7903_1231_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1231
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Sales and Marketing at Bode Technology, whom Prolacta engaged to perform the DNA matching. At that time, Bode had never extracted DNA from breast milk. After six months of refining its process, Bode met Prolacta\rquote s DNA matching requirements.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Bode also published an article about detecting through DNA analysis a minor contributor from mixed samples of human milk. At the time, Bode performed a literature search on the topic of isolating and extracting DNA from breast milk. Bode found two articles. One related to RNA extraction from epithelial cells in breast milk. The other was a feasibility study on isolating DNA in breast milk for epidemiologic studies of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib73a5554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
breast cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Nagy states in his declaration that using DNA in human milk to create a genetic link between human milk and a screened donor and to detect and exclude mixtures of milk containing DNA from unknown and unscreened donors was a completely new application in the field of DNA analysis. He notes that the two articles did not discuss using breast milk DNA in the manner developed by Prolacta.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
One problem with Prolacta\rquote s argument and Nagy\rquote s declaration is that, as discussed above, nothing in the claims requires screening of the donor. Thus, the \u8220\'3fcompletely new application\u8221\'3f discussed by Nagy\u8212\'3fthe genetic link between screened donors and donated milk and excluding milk containing DNA from unknown and unscreened donors\u8212\'3fis not the application in the claims. The claims merely require matching to identify that the donated mammary fluid is from a specific subject, regardless of whether that subject has been screened for health problems or drug use. Using DNA to match a person\rquote s identity is not a new or inventive use.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Another problem with Prolacta\rquote s argument and Nagy\rquote s declaration is that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 defines identity marker and mammary fluid much more broadly than Nagy\rquote s discussion of breast milk and DNA. Mammary fluid is not just breast milk and colostrum, but also includes 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fsolid fractions of the mammary fluid, whole cells or cellular constituents, proteins, glycoproteins, peptides, nucleotides (including DNA and RNA polynucleotides), and other like biochemical and molecular constituents of breast milk.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at 4:24-33. The patent defines \u8220\'3fidentity marker\u8221\'3f as \u8220\'3fa marker that can be used to identify an individual subject,\u8221\'3f including, but not limited to, any \u8220\'3fgenes, alleles, loci, antigens, polypeptides, or peptides.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:34-38. The claim term \u8220\'3fidentity marker profile\u8221\'3f is defined to mean any profile of identity markers that can identify one human from 100,000, 1 million, or 5 million humans. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:39-45. The claims thus do not require the matching be through maternal DNA or the process described by Nagy. Any identity marker will suffice.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta and Nagy\rquote s attempt to distinguish the two other articles relating to breast milk are not persuasive given the text of the claims. That one article involved RNA is not dispositive because mammary fluid is defined to include RNA polynucleotides. That the articles do not discuss using DNA to match donors screened for health problems to create a safe milk product is not relevant because the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 also do not require this use. Accordingly, the mere concept of finding DNA in mammary fluid was not new or inventive, and the new or inventive use as discussed by Nagy is not what is in the patent claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 acknowledges that obtaining identity markers was known in the art and that testing identity markers also was known in the art. Using such tests to match a subject\rquote s identity is not new or inventive. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_754&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_754" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d at 754
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that \u8220\'3fapplying standard techniques 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1232_97}{\*\bkmkend co_pp_sp_7903_1232_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1232
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a standard way to observe a natural law does not provide an inventive concept\u8221\'3f). Because that is all the claims cover, the claims add no new or inventive concept not already known in the art. Considering the steps \u8220\'3fas an ordered combination adds nothing to the laws of nature that is not already present when the steps are considered separately.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_79&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_79" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 79, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, Prolacta\rquote s argument that applying DNA markers to mammary fluid was itself the inventive concept cannot support a finding at step two. \u8220\'3fThis is because \u8216\'3f[t]he inventive concept necessary at step two ... cannot be furnished by the unpatentable law of nature ... itself.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_754&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_754" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d at 754
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alterations in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims cover laws of nature\u8212\'3fidentity markers that exist in a subject and mammary fluid with nutrient levels that occur in nature. The remaining steps (testing the identity markers for a match, pasteurization) \u8220\'3fconsist of well-understood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_780_79&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_79" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 79-80, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims, thus, fail at step two.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43c724c1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43c724c1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43c724c1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43c724c1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B162047531000_97}{\*\bkmkend co_anchor_B162047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q also asserts that it does not perform the \u8220\'3fwherein a match\u8221\'3f step of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and thus has not literally infringed the patent or infringed the patent under the doctrine of equivalents. The Federal Circuit has discussed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 56
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 burden shifting in the context of a motion for summary judgment of noninfringement as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As the movant, Dow had \u8220\'3fthe initial responsibility of identifying the legal basis of its motion, and of pointing to those portions of the record that it believes demonstrates the absence of a genuine issue of material fact.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001936019&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1046&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1046" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Novartis Corp. v. Ben Venue Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 271 F.3d 1043, 1046 (Fed. Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dow satisfied this burden by identifying that its accused process lacks a \u8220\'3fpressurized collection vessel,\u8221\'3f as construed, and by pointing to record evidence suggesting that, in its process, \u8220\'3fthe material continuously passed through the heat exchangers.\u8221\'3f J.A. 914 (\u8220\'3fDow\rquote s dispersion is only collected at the very end of the Dow process in a large open-to-the-atmosphere plastic crate or an even larger, open-to-the-atmosphere storage tank, neither of which is pressurized.\u8221\'3f). Accordingly, \u8220\'3fthe burden shift[ed] to [Akzo] to designate specific facts showing that there is a genuine issue for trial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001936019&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1046&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1046" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Novartis
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 271 F.3d at 1046
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. The court correctly determined that Akzo failed to meet that burden.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038192322&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1341&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1341" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Akzo Nobel Coatings, Inc. v. Dow Chem. Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 811 F.3d 1334, 1341 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alterations in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties stipulated to the definition of \u8220\'3fwherein a match\u8221\'3f as: \u8220\'3fa determination that the marker(s) in the biological sample and donated fluid or milk are the same and that there are no additional unmatched marker(s).\u8221\'3f Ni-Q argues that this definition encompasses two different steps and that it has never performed the second step, determining that there are no additional unmatched markers. Prolacta responds that determining that the reference sample and milk sample are the same necessarily requires a finding that there are no unmatched markers and that Ni-Q\rquote s laboratory does perform the test for unmatched markers and thus Ni-Q has infringed the patent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court agrees that the definition stipulated to by the parties encompasses two separate determinations: (1) a determination 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1233_97}{\*\bkmkend co_pp_sp_7903_1233_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1233
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that the marker in the reference sample and donated milk are the same; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (2) a determination that there are no additional unmatched markers. The definition connects the two clauses with the conjunction \u8220\'3fand,\u8221\'3f which shows that both items are part of the \u8220\'3fdetermination\u8221\'3f that is encompassed in the definition. Indeed, this is precisely how Prolacta urged the Court to define the term before the parties stipulated to the definition. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ECF 43 at 15 (\u8220\'3fAccordingly, the \u8216\'3fwherein a match\u8217\'3f limitation should be construed to require (1) an affirmative determination that the markers in the biological sample and donated fluid or milk are the same 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (2) that there are no additional unmatched markers.\u8221\'3f (emphasis in original) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Genetics Associates performed Ni-Q\rquote s testing on its donated breast milk.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032047531000_ID0EOFBI_97}{\*\bkmkend co_fnRef_B00032047531000_ID0EOFBI_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032047531000_97" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ni-Q instructed Genetics Associates to: (1) identify identity marker profiles in buccal swab samples Ni-Q collected from its milk donors; (2) identify identity marker profiles in milk samples Ni-Q provided to Genetics Associates; (3) compare those profiles; and (4) advise Ni-Q whether the markers match. Ni-Q did not consider contamination and thus never instructed Genetics Associates to test whether the milk samples contained unmatched markers. Ni-Q maintained the raw milk to be processed and the database linking the samples provided to Genetics Associates and the larger volume of raw milk. Ni-Q also processed the milk. Genetics Associates played no role in processing the milk.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In setting up its testing protocol, Genetics Associates validated both identity matching protocols and protocols for testing for contamination at a certain threshold. It discovered that its methods allowed it to detect contamination at levels above 20 percent. Genetics Associates\rquote  test could not discern contamination at levels below 20 percent. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
One method of determining contamination was from electropherograms revealing additional peaks beyond what one would expect from a single sample. Ni-Q did not receive those electropherograms, but Genetics Associates would review them to determine whether to retest a sample or whether a sample was not a match because of contamination.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ni-Q argues that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 requires 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
a determination that the milk processed
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 had no additional unmatched markers, and because Ni-Q processed the milk and did not make that determination before processing, Ni-Q did not infringe the patent. Therefore, argues Ni-Q, even if Genetics Associates\rquote  test provides results relating to unmatched markers for a representative sample of milk, that does not make Ni-Q\rquote s processing of milk infringing. Ni-Q provides as an example the one sample rejected by Genetics Associates for contamination\u8212\'3fthe sample was contaminated by another sample in shipping to Genetics Associates. Genetics Associates\rquote  test results related to the small sample it was provided, but Genetics Associates made no \u8220\'3fdetermination\u8221\'3f regarding unmatched markers relating to the gallons of milk sitting in Ni-Q\rquote s warehouse. Ni-Q also argues that Prolacta cannot rely on Genetics Associates\rquote  test to assert infringement because Genetics Associates\rquote  test can only detect unmatched markers above 20 percent contamination.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Genetics Associates\rquote  inability to detect unmatched markers below 20 percent contamination renders its test non-infringing. The definition of \u8220\'3fwherein a match\u8221\'3f requires \u8220\'3fno\u8221\'3f unmatched markers. The test by Genetics Associates allows for unmatched markers up to 20 percent and, thus, does not meet the claim\rquote s requirements. Additionally, the claim definition requires a determination that the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
milk processed
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 had no additional unmatched 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1234_97}{\*\bkmkend co_pp_sp_7903_1234_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1234
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 markers (not the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
milk tested
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). It is undisputed that Ni-Q made the determination regarding what milk to process. Ni-Q did not consider whether there were unmatched markers in making its determination regarding what milk to process.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, the fact that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetics Associates
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 makes some determination of unmatched markers does not automatically make 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ni-Q
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 liable for patent infringement. Prolacta cites 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Akamai Techs., Inc. v. Limelight Networks, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d 1020 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for the proposition that the conduct of Genetics Associates can be attributable to Ni-Q for purposes of infringement. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Akamai
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit held:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Where more than one actor is involved in practicing the steps, a court must determine whether the acts of one are attributable to the other such that a single entity is responsible for the infringement. We will hold an entity responsible for others\rquote  performance of method steps in two sets of circumstances: (1) where that entity directs or controls others\rquote  performance, and (2) where the actors form a joint enterprise.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
To determine if a single entity directs or controls the acts of another, we continue to consider general principles of vicarious liability. In the past, we have held that an actor is liable for infringement under \u167\'3f 271(a) if it acts through an agent (applying traditional agency principles) or contracts with another to perform one or more steps of a claimed method. We conclude, on the facts of this case, that liability under \u167\'3f 271(a) can also be found when an alleged infringer conditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1022&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1022" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1022-23
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (footnotes and citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prolacta argues that Ni-Q directs and controls Genetics Associates because it conducts testing under a contract with Ni-Q and under Ni-Q\rquote s direction and because Genetics Association accessed benefits by performing steps of the patented method identified by Ni-Q and under the terms prescribed by Ni-Q. The flaw in Prolacta\rquote s argument is that the undisputed evidence in the record is that Ni-Q did not direct Genetic Associates to test for unmatched markers, provide terms under which the milk should be tested for unmatched markers, or condition Genetic Associates\rquote  payment for testing on performing a test for unmatched markers. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040522210&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_948&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_948" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Medgraph, Inc. v. Medtronic, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 843 F.3d 942, 948 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming summary judgment of noninfringement when \u8220\'3fthe evidence presented to the district court indisputably shows that Medtronic does not condition the use of, or receipt of a benefit from, the CareLink System on the performance of all of Medgraph\rquote s method steps\u8221\'3f). Ni-Q, therefore, has not literally infringed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B172047531000_97}{\*\bkmkend co_anchor_B172047531000_97}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B182047531000_97}{\*\bkmkend co_anchor_B182047531000_97}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
It also does not appear that Prolacta is asserting infringement through the doctrine of equivalents. Prolacta did not respond to this portion of Ni-Q\rquote s motion. Even if Prolacta is making such an assertion, Ni-Q also did not infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under the doctrine of equivalents. This type of infringement requires a finding \u8220\'3fthat the accused product or method performs the substantially same function in substantially the same way with substantially the same result as each claim limitation of the patented product or method.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011551577&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1326&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1326" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AquaTex Indus., Inc. v. Techniche Sols.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 479 F.3d 1320, 1326 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fA patentee must establish \u8216\'3fequivalency on a limitation-by-limitation basis\u8217\'3f by \u8216\'3fparticularized testimony and linking argument\u8217\'3f as to the insubstantiality of the differences between the claimed invention and the accused 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_1235_97}{\*\bkmkend co_pp_sp_7903_1235_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1235
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 device or process.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038192322&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1342&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1342" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Akzo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 811 F.3d at 1342
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1996165801&pubNum=0000506&originatingDoc=I684ad680307611e987fd8441446aa305&refType=RP&fi=co_pp_sp_506_1566&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1566" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Texas Instruments Inc. v. Cypress Semiconductor Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 90 F.3d 1558, 1566 (Fed. Cir. 1996)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The purpose of the second step of the \u8220\'3fwherein a match\u8221\'3f requirement\u8212\'3fmaking sure there are \u8220\'3fno unmatched markers\u8221\'3f\u8212\'3fis to prevent contamination from unscreened donors. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at 2:3-9; 10:21-30; ECF 99 at 4 (Declaration of Martin L. Lee, \u182\'3f 10). Ni-Q does nothing equivalent to that step to prevent contamination from other donors. Summary judgment in favor of Ni-Q, is, therefore, appropriate.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I43ce77c1f63b11ebb275b828b3160}{\*\bkmkend co_anchor_I43ce77c1f63b11ebb275b828b3160}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
CONCLUSION
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff Ni-Q, LLC\rquote s Motion for Summary Judgment (ECF 88) is GRANTED. The Court finds that there are no genuine issues of material fact, the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I684ad680307611e987fd8441446aa305&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and Plaintiff has not infringed the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032538801&pubNum=0004074&originatingDoc=I684ad680307611e987fd8441446aa305&refType=PA&docFamilyGuid=I8c9eb0207da611e39050a27cbc9f10b0&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 921 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 even if they were valid.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IT IS SO ORDERED.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_97}{\*\bkmkend co_allCitations_97}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
367 F.Supp.3d 1221
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012047531000_97}{\*\bkmkend co_footnote_B00012047531000_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012047531000_ID0EKQBG_97" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Although Ni-Q raised arguments related to the other asserted claims, Prolacta focused its arguments on the representative Claim 1.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022047531000_97}{\*\bkmkend co_footnote_B00022047531000_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022047531000_ID0EJGAI_97" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Prolacta contends that the Court\rquote s claim construction requires that Prolacta \u8220\'3fcherry pick\u8221\'3f and only process mammary fluid that naturally meets the nutritional limitations set out in Claim 1. That is an unreasonable interpretation of the Court\rquote s claim construction. The Court noted that the patent describes that most donated mammary fluid does not fall within the nutrient limitations, but the patent does not suggest that mammary fluid 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
always
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 falls outside the nutrient level requirements of Claim 1. The Court thus found that Claim 1 did not 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
necessarily
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 require altering the nutritional content or filtering the donated mammary fluid. It merely required that the nutritional levels be met after processing is complete. Thus, if donated mammary fluid naturally falls within the nutrient level limitations, the only processing step that would be required for that donated milk under the text of Claim 1 is pasteurization. The Court noted that the patent sets out five types of processing. The other types of processing are involved when the nutrient levels are not naturally met by the donated mammary fluid, and in some of the other claims of the patent. That is why the Court\rquote s construction of processing is: \u8220\'3fOne 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
or more
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 of the following: filtering, heat-treating, separating into cream and skim, adding cream to the skim, or pasteurizing.\u8221\'3f (emphasis added). If the Court\rquote s construction required processing only the mammary fluid that already met the nutrient level limitations, then the only processing step would be pasteurization and the \u8220\'3for more\u8221\'3f steps of filtering, separating into cream and skim, and adding cream to skim would be superfluous.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032047531000_97}{\*\bkmkend co_footnote_B00032047531000_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032047531000_ID0EOFBI_97" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Ni-Q stopped testing donated breast milk in approximately July 2017.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }